RET and non-small cell lung carcinoma: Over the past decade, the treatment of RET-fusion-positive NSCLC patients has evolved from chemotherapy alone to multi-kinase inhibitor (MKI) to selective RET (tyrosine kinase inhibitors) (RET-TKI) nowadays.